← Leaderboards
Christopher L King
Case Western Reserve University
$14,576,924
Attributed
$14,576,924
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$14,576,924 · 9
VA$0 · 1
By mechanism
R01$8,784,326 · 3
U01$3,352,146 · 1
U19$2,440,452 · 5
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- James Walter Kazura$29,330,012
- Edwin Michael$976,265
- Jane M. Olson$4,672,068
- Nicholas Joseph Schork$17,276,274
- David R Setzer$1,121,100
Others in their field
Top investigators on “Immunity”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmunityBloodInfectionMalariaAntibodiesB-LymphocytesAntigensErythrocytesVaccinesAreaImmuneParasitesImmune ResponseResponseProteinsMediatingPlasmodium FalciparumExposure ToIn VitroAffectTransmission ProcessStagingMorbidity - Disease RatePhenotype
Grant awards (47)
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies$697,088
R01 · FY2024 · AI · contact PI
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections$303,268
U01 · FY2024 · CA · contact PI
Defining targets of protective immunity in Plasmodium vivax using human monoclonal antibodies$0
I01 · FY2024 · VA · contact PI
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections$1,004,770
U01 · FY2023 · CA · contact PI
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies$706,868
R01 · FY2023 · AI · contact PI
Defining targets of protective immunity in Plasmodium vivax using human monoclonal antibodies$0
I01 · FY2023 · VA · contact PI
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies$706,742
R01 · FY2022 · AI · contact PI
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections$679,626
U01 · FY2022 · CA · contact PI
Defining targets of protective immunity in Plasmodium vivax using human monoclonal antibodies$0
I01 · FY2022 · VA · contact PI
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies$714,622
R01 · FY2021 · AI · contact PI
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections$1,364,482
U01 · FY2020 · CA · contact PI
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies$774,283
R01 · FY2020 · AI · contact PI
Immunology core$52,824
U19 · FY2017 · AI · contact PI
Strain-specific Immunity to Plasmodium vivax malaria$0
I01 · FY2017 · VA · contact PI
Pathogenesis$182,749
U19 · FY2016 · AI · contact PI
Strain-specific Immunity to Plasmodium vivax malaria$0
I01 · FY2016 · VA · contact PI
Fetal Immunity of Malaria$414,025
R01 · FY2015 · AI · contact PI
Pathogenesis$184,728
U19 · FY2015 · AI · contact PI
Strain-specific Immunity to Plasmodium vivax malaria$0
I01 · FY2015 · VA · contact PI
Fetal Immunity of Malaria$399,343
R01 · FY2014 · AI · contact PI
IgG-mediated modulation of antibody production and B cell memory to malaria: Rol$221,334
U19 · FY2014 · AI · contact PI
Pathogenesis$181,326
U19 · FY2014 · AI · contact PI
Strain-specific Immunity to Plasmodium vivax malaria$0
I01 · FY2014 · VA · contact PI
Fetal Immunity of Malaria$361,356
R01 · FY2013 · AI · contact PI
IgG-mediated modulation of antibody production and B cell memory to malaria: Rol$195,668
U19 · FY2013 · AI · contact PI
Pathogenesis$176,654
U19 · FY2013 · AI · contact PI
Fetal Immunity of Malaria$375,343
R01 · FY2012 · AI · contact PI
Pathogenesis$280,890
U19 · FY2012 · AI · contact PI
IgG-mediated modulation of antibody production and B cell memory to malaria: Rol$235,750
U19 · FY2012 · AI · contact PI
Fetal Immunity of Malaria$406,651
R01 · FY2011 · AI · contact PI
Pathogenesis$161,131
U19 · FY2011 · AI · contact PI
Pathogenesis$160,394
U19 · FY2010 · AI · contact PI
Fetal Immunity to Falciparum Malaria$359,276
R01 · FY2009 · AI · contact PI
New Approaches to Schistosome vaccine antigen discovery$385,690
R01 · FY2008 · AI · contact PI
Fetal Immunity to Falciparum Malaria$359,276
R01 · FY2008 · AI · contact PI
New Approaches to Schistosome vaccine antigen discovery$375,071
R01 · FY2007 · AI · contact PI
Fetal Immunity to Falciparum Malaria$366,235
R01 · FY2007 · AI · contact PI
Fetal Immunity to Falciparum Malaria$377,173
R01 · FY2006 · AI · contact PI
New Approaches to Schistosome vaccine antigen discovery$364,336
R01 · FY2006 · AI · contact PI
Fetal Immunity to Falciparum Malaria$328,313
R01 · FY2005 · AI
New Approaches to Schistosome vaccine antigen discovery$312,635
R01 · FY2005 · AI
CORE--IMMUNOLOGY FACILITY$0
U19 · FY2002 · AI
PRENATAL SENSITIZATION TO W BANCROFTI$0
U19 · FY2002 · AI
CORE--IMMUNOLOGY FACILITY$0
U19 · FY2001 · AI
PRENATAL SENSITIZATION TO W BANCROFTI$0
U19 · FY2001 · AI
CORE--IMMUNOLOGY FACILITY$203,502
U19 · FY2000 · AI
PRENATAL SENSITIZATION TO W BANCROFTI$203,502
U19 · FY2000 · AI